Immuneering (IMRX) Research & Development (2020 - 2026)
Immuneering (IMRX) posted quarterly Research & Development of $10.6 million for Q1 2026, down 7.2% year-over-year from $11.5 million in Q1 2025, and up 15.03% quarter-over-quarter from $9.3 million in Q4 2025.
Immuneering (IMRX) Research & Development (2020 - 2026) Analysis & Trends
Immuneering's Research & Development history runs 7 years deep, the most recent figure standing at $10.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 7.2% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $41.2 million (down 14.54% YoY), while the FY2025 annual figure was $42.0 million, down 12.33% from the prior year.
- Research & Development for Q1 2026 stood at $10.6 million, up from $9.3 million in the prior quarter.
- The five-year high for Research & Development was $14.9 million in Q4 2024, with the low at $8.0 million in Q2 2022.
- The 5-year median for Research & Development is $10.5 million (2025), against an average of $10.5 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 68.03% in 2022, then slumped 37.71% in 2025.
- Immuneering's Research & Development stood at $9.9 million in 2022, then increased by 20.65% to $11.9 million in 2023, then rose by 24.74% to $14.9 million in 2024, then plunged by 37.71% to $9.3 million in 2025, then climbed by 15.03% to $10.6 million in 2026.
- Business Quant data shows IMRX's Research & Development at $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.00 Mn |
| Mar 31, 2026 | 10.65 Mn |
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 10.87 Mn |
| Jun 30, 2025 | 10.45 Mn |
| Mar 31, 2025 | 11.47 Mn |
| Dec 31, 2024 | 14.86 Mn |
| Sep 30, 2024 | 11.25 Mn |
| Jun 30, 2024 | 10.65 Mn |
| Mar 31, 2024 | 11.20 Mn |
| Dec 31, 2023 | 11.91 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 10.21 Mn |
| Dec 31, 2022 | 9.87 Mn |
| Sep 30, 2022 | 9.36 Mn |
| Jun 30, 2022 | 7.98 Mn |
| Mar 31, 2022 | 9.06 Mn |
| Dec 31, 2021 | 7.95 Mn |
| Sep 30, 2021 | 6.21 Mn |